Form 4: Monopar CEO Chandler Robinson Acquires Equity Awards

Monopar Therapeutics CEO Chandler Robinson acquired 16,753 stock options and 49,133 restricted stock units as part of compensation.

Summary

• Chandler Robinson, Chief Executive Officer and Director of Monopar Therapeutics (MNPR), acquired derivative securities.
• The transaction occurred on December 2, 2025, and was made pursuant to a Rule 10b5-1 plan.
• Robinson acquired 16,753 stock options with an exercise price of $75.94 per share.
• These stock options will vest 6/48ths on June 30, 2026, and 1/48th per month thereafter, expiring on December 2, 2035.
• Robinson also acquired 49,133 Restricted Stock Units (RSUs).
• The RSUs will vest 6/48ths on June 30, 2026, and 3/48ths per quarter thereafter.
• Following these transactions, Robinson beneficially owns 16,753 stock options and 121,732 Restricted Stock Units directly.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it reflects a routine executive compensation grant, which aligns management's interests with shareholders. It does not indicate any immediate operational or financial changes, but rather a standard incentive mechanism.

Positives

• The acquisition of stock options and restricted stock units by the CEO aligns management's long-term interests with those of shareholders, incentivizing performance and value creation.

Future Outlook

The vesting schedules for the acquired stock options and Restricted Stock Units extend into future periods, indicating a long-term incentive structure for the CEO's continued tenure and performance.

Industry Context

The grant of equity compensation, such as stock options and restricted stock units, is a standard practice across various industries, particularly in biotechnology and pharmaceuticals, to attract, retain, and motivate key executives. This aligns executive incentives with long-term shareholder value creation.

Comparison to Industry Standards

• Equity compensation, including stock options and restricted stock units, is a common practice in the biotechnology and pharmaceutical industries to incentivize executives and align their interests with long-term shareholder value.
• The structure of vesting over several years, with initial and subsequent periodic vesting, is typical for executive grants in comparable companies, ensuring sustained commitment and performance.

Stakeholder Impact

• Shareholders: The equity grants are designed to align the CEO's financial interests with shareholder value creation, potentially leading to more focused long-term strategic decisions.
• Employees: While not directly impacting all employees, executive compensation structures can influence overall company culture and compensation philosophy.

Next Steps

• The stock options will begin vesting on June 30, 2026, with subsequent monthly vesting.
• The Restricted Stock Units will begin vesting on June 30, 2026, with subsequent quarterly vesting.

Key Dates

Recommendation

This Form 4 reports a routine grant of equity compensation to the CEO, Chandler Robinson, consisting of stock options and restricted stock units. Such grants are standard practice to align executive interests with shareholder value creation and do not inherently alter the company's fundamental investment thesis or operational outlook. Therefore, a 'hold' recommendation is appropriate as this filing does not present new information warranting a change in investment strategy.

Keywords

Monopar Therapeutics, MNPR, Chandler Robinson, CEO, Stock Options, Restricted Stock Units, Equity Compensation, Insider Transaction, Form 4